Introduction {#sec1-1}
============

Although gastric cancer is considered as the third most frequent cancer-related death worldwide, it remains the major cause of cancer mortality, with nearly 10,000 deaths per year in Iran (Fitzmaurice et al., 2015). One of most the important features of this type of cancer is the absence of clinical symptoms in the early stages of disease. More than 80% of the diagnosis of this type of cancer is made at the late stages of the disease (Siegel et al., 2011). Timely and correct diagnosis of gastric cancer in the early stages is crucial for efficacy of the treatment which results in higher survival of patients. Although traditional endoscopy and microscopic examinations have important roles in diagnosis of gastric cancer, these methods are invasive and inappropriate for regular screening (Liu et al., 2011). On the other hand, conventional biomarkers such as carcino-embryonic antigen (CEA) and carbohydrate antigens 19-9 and 125 (CA 19-9 and CA 125) do not have adequate sensitivity and specificity in the early diagnosi (Yin et al., 2012). MicroRNAs (miRNAs) have the capability to be considered as diagnostic biomarkers for cancer (Wang et al., 2016a). These non-coding small RNAs regulate gene expression at the post-transcriptional level and play important roles in many aspects of biology, including tissue development and degeneration, apoptosis, response to cellular stresses, and etiology and progression of various diseases (Filipowicz et al., 2008; Mondanizadeh et al., 2015). Furthermore, the expression of miRNAs is frequently deregulated in cancer and they may act as either oncogenes or tumor suppressors (Rotkrua et al., 2013). Several reports have shown that miRNAs are stable in plasma and serum and that circulating molecules display unique profiles for each tumor. The stability of miRNAs in circulation might be due to their protection by exosome and microvesicle, Argonaute2 (Ago2), and high-density lipoprotein (Filipowicz et al., 2008; Tsujiura et al., 2010; Rotkrua et al., 2013). It was also shown that miRNAs can be used as molecular biomarkers for the diagnosis and progression evaluation of several cancers (Cortez et al., 2011; Song and Meltzer, 2012). A few studies have evaluated the expression profiles of different miRNAs in gastric cancer and tried to use them to distinguish patients from healthy individuals (Zhang et al., 2008; Xie et al., 2016). In a study conducted in mice model of diffuse-type gastric cancer (DGC), Rotkrua et al. assessed four miRNAs, miR-103, miR-107, miR-194 and miR-210, using microarray data, and reported that they are significantly overexpressed in the animal model(Rotkrua et al., 2013). It was proposed that these miRNAs can be used as novel non-invasive biomarkers for the early detection of DGC.

Considering the fact that the major type of gastric cancer in Iranian population is the intestinal-type (IGC), in the current study, the plasma levels of miR-103, miR-107, miR-194 and miR-210 were compared between IGC patients and healthy controls, using reverse transcription quantitative real-time PCR (RT-qPCR), to evaluate their diagnostic utility as noninvasive biomarkers for IGC detection.

Materials and Methods {#sec1-2}
=====================

Patients and samples {#sec2-1}
--------------------

A total of 100 plasma samples, including 50 preoperative samples from patients with IGC and 50 samples from healthy individuals, were enrolled in this study. The IGC samples were obtained from Iran Tumor Bank (Cancer Institute, Imam Khomeini Hospital, Tehran Iran), which were related to 22 female and 28 male, with a median age of 56 years (range, 29 to 80 years). The patients who had no sign of metastasis at the time of specimen collections and had not been received cancer-related treatment were enrolled in this study. The specimens of the patients who received any type of cancer treatment or diagnosed with proven metastasis of tumor to other organs were excluded during sample collection. The pathological classifications of GC patients were according to the IGCC/TMN staging system (Wittekind et al., 2002). Other clinical characteristics of the patients are detailed in [Table 1](#T1){ref-type="table"}.

###### 

Baseline Characteristics of Patients and Control Groups

  Parameter                      Patients Number (%)   Healthy controls Number (%)
  ------------------------------ --------------------- -----------------------------
  Gender                                               
   Female                        22 (44)               22 (44)
   Male                          28 (56)               28 (56)
  Age                                                  
   Mediam                        56                    52
   Range                         29-80                 26-65
  TNM stage                                            
   I                             8                     
   II                            10                    
   III                           20                    
   IV                            12                    
  Haematogenous metastasis (M)                         
   No metastasis (M0)            38                    
   Metastasis (M1)               12                    
  Lymph node metastasis (N)                            
   No metastasis (N0)            18                    
   Metastasis (N1-N3)            32                    
  Depth of invasion (T)                                
   T1                            2                     
   T2                            11                    
   T3                            37                    

The samples from healthy individuals were obtained from Arak Reference Laboratory (Arak University of Medical Sciences, Arak, Iran) and they were matched with the samples in the patient group, based on the age and gender criteria ([Table 1](#T1){ref-type="table"}). All samples were stored at -80°C prior to analysis. The study was approved by the Ethics Committee of Arak University of Medical Sciences (Ethics number, 2143).

RNA Extraction {#sec2-2}
--------------

Total RNA was extracted using RNX-Plus reagent (SinaClon, Iran) with some modifications to the manufacturer\`s protocol, to optimize the reagent for isolation of small RNAs. Briefly, 200 μl of plasma was mixed with 1ml RNX-Plus solution and incubated at room temperature for 5 min. After phase separation by adding 200 μl chloroform and incubation at 4°C for 5 min, the aqueous phase was separated and mixed with 2 volumes of absolute ethanol and incubated at -20°C overnight. After centrifugation at 4°C for 60 min, the RNAs were eluted in 20 μl RNase-free water and the extracted RNA was used directly for reverse transcription step.

Reverse transcription {#sec2-3}
---------------------

Stem-loop primers were used for reverse transcription of mature miRNAs (Chen et al., 2005).The sequences of Stem-loop and gene-specific primers are summarized in [Table 2](#T2){ref-type="table"}. For cDNA synthesis, about 1μg of RNA was mixed with 1 pmol of specific stem-loop RT primers and incubated at 75°C for 5 min. A mix containing 100 units of M-MuLVRT-enzyme (Vivantis, Malaysia), 1x RT-buffer, and 400 μMdNTP were added to the tube. Finally, RT reaction mixtures were incubated at 25°Cfor 15 min, 37°C for 15 min, 42°C for 45 min, and 10 min at 75°C, in a thermal cycler instrument (Eppendorf, Germany). The resulting cDNAs were stored at -20°C prior to RT-qPCR analyses.

###### 

Primers Used for Reverse-Transcription and RT-qPCR Assay of the Target miRNAs

  Target                            Primer sequences (5\`-3\`)
  --------------------------------- -------------------------------------------------------------------
  miR-103                           Sa: 5\`-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACCAAGGCA-3\`
  Fb: 5\`-GCTTCTTTACAGTGCTGCC-3\`   
  miR-107                           S: 5\`-GTCGTATCGAGAGCAGGGTCCGAGGTATTCGCACTCGATACGACAGCAGCA-3\`
  F: 5\`-GCCCTGTACAATGCTGC-3\`      
  miR-194                           S: 5\`-GTCGTATCGAGA GCAGGGTCCGAGGTATT CGCACTCGATACGACTC CACAT-3\`
  F: 5\`-TGTAACAGCAACTCCATGTG-3\`   
  miR-210                           S: 5\`-GTCGTATCGAGAGCAGGGTCCGAGGTATT CGCACTCGATA CGACCAGTGTG-3\`
  F: 5\`-CTGCCCACCGCACACTG-3\`      
  SNORD47                           S: 5\`-GTCGTATGCAGAGCAGGGTCCGAGGTATTCGCACTGCATACGACAACCTCA-3\`
  F: 5\`-ATCACTGTAAAACCGTTCCA-3\`   
  Common Reverse                    5\`-AGAGCAGGGTCCGAGGT-3\`

^a^ , Stem-loop gene-specific reverse-transcriptase primers; ^b^ , Specific forward primers for RT-qPCR amplification

Quantitative real-time PCR {#sec2-4}
--------------------------

Expression of SNORD47 (U47) RNA was used as endogenous reference gene for normalization of miRNAs expressions. The sequences of forward and the universal reverse primers are summarized in [Table 2](#T2){ref-type="table"}. RT-qPCR reactions were performed in a LightCycler®96 instrument(Roche, Germany) using the QuantiNova SYBR Green PCR Kit (Qiagen, Germany).The amplification profile consisted of a single cycle of enzyme activation at 95°C for 2 min followed by 40 cycles of denaturation at 95°C for 5 sec and annealing/extension at 60°C for 15 sec, with a single fluorescence acquisition at channel green. Melting curve analysis was carried out following amplification with a ramp rate of 0.2°C/second to 96°Cwith continuous fluorescence acquisition. The relative expression was calculated by the comparative Cq method using the relative expression software tool (REST) (Pfaffl et al., 2002).

Statistical methods {#sec2-5}
-------------------

RT-qPCR data were analyzed by REST 2009 and the data in graphs were expressed as the mean ± SE. The differences between groups were compared by analysis of variance (ANOVA). Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic value of the plasma miRNA levels for IGC. All statistical analyses were calculated using SPSS software (version 16; SSPS Inc., 184 Chicago). P-values of \<0.05 were considered to indicate statistical significance.

Results {#sec1-3}
=======

Evaluation of RT-qPCR for measuring miRNAs plasma levels {#sec2-6}
--------------------------------------------------------

The results of RT-qPCR analyses showed that in comparison to healthy individuals, the plasma levels of miR-107 (0.147 fold, P= 0.002), miR-194 (0.117 fold, P= 0.001), and miR-210 (0.159 fold, P= 0.002) were significantly lower in IGC patients. However, the expression of miR-103 exhibited no significant difference between the healthy controls and IGC patients (0.889 fold, P= 0.77) ([Figure 1](#F1){ref-type="fig"}).

![Expression Levels of the miR-103, miR-107, miR-195, and miR-210 in IGC Patients. Error bars indicate the standard error of the mean. \*\*P \< 0.01, significantly different from control group.](APJCP-20-1421-g001){#F1}

Expression of the miRNAs in different clinicopathological status {#sec2-7}
----------------------------------------------------------------

The plasma levels of miR-107, miR-194, and miR-210 were analyzed in patients with different TNM stages. As shown in [Figure 2](#F2){ref-type="fig"}, the expression levels of the three miRNAs were not significantly different among patients with stages I-IV of IGC. Nevertheless, in comparison to control group, patients with stages I-IV for miR-107 (P\< 0.01) and stages II-IV for miR-194 (P\< 0.01) and miR-210 (P\< 0.05) had reduced plasma levels. The plasma levels of miR-194 and miR-210 in patients with stage I were not significantly different from control group (P= 0.174 and P= 0.095, respectively). Furthermore, the plasma levels of the three miRNAs were evaluated based on the depth of invasion, haematogenous metastasis, and lymph node metastasis. The results showed that the level of the three miRNAs were not significantly different ([Figure 2](#F2){ref-type="fig"}).

![Plasma Concentrations of miR-107, miR-194, and miR-210 in Different Clinicopathological Status. The Plasma Levels of miR-107, miR-194, and miR-210 Are Shown in Figure a-c, Respectively. Error bars indicate standard deviation. Statistically significant results are shown by asterisks (\*P \< 0.05, \*\*P \< 0.01). The P-values of insignificant comparisons are shown above the horizontal bars.](APJCP-20-1421-g002){#F2}

Determination of expression level cutoff {#sec2-8}
----------------------------------------

ROC curve analyses were performed to determine diagnostic values for miR-107, miR-194, and miR-210 to differentiate IGC patients from healthy individuals. The cutoff levels were chosen as the point with the maximum sum of sensitivity and specificity on the ROC curves using the Youden\`s index (\[sensitivity + specificity\] -1) (Khansarinejad et al., 2015). Based on the results shown in [Figure 3](#F3){ref-type="fig"}, at the cutoff level of 0.504, miR-107 exhibited 93.8% sensitivity and 78.8% specificity with an AUC of 0.947. For miR-194, the cutoff level of 0.266 showed 87.5% sensitivity and 75.8% specificity, with an AUC of 0.862. Finally, at the cutoff level of 0.394, miR-210 exhibited 100% sensitivity and 72.7% specificity with an AUC of 0.82 ([Figure 3](#F3){ref-type="fig"}).

![Receiver Operating Characteristic (ROC) Curve Analyses Corresponds to miR-107, miR-194, and miR-210 Expression Levels to Discriminate IGC Patients from Healthy Ones Individuals. a, The area under the curve of miR-107; b, The area under the curve of miR-194; c, The area under the curve of miR-210.](APJCP-20-1421-g003){#F3}

Discussion {#sec1-4}
==========

Several studies have shown alterations in microRNA expression in patients with gastric cancers and suggested circulating microRNAs as novel biomarkers (Calin and Croce, 2006; Komatsu et al., 2013). It has been shown that the expression levels of miR-21, miR-221, miR-223, miR-106, miR-17-5p, miR-19b, miR-194, miR-744 and miR-376 were significantly upregulated in these patients (Zhou et al., 2010; Li et al., 2012; Song et al., 2012; Wang et al., 2014; Tsujiura et al., 2015), whereas miR-218, miR-143, miR-195, miR-141, miR-1233, and let-7a were downregulated (Li et al., 2012; Wang et al., 2013; Huang and Yu, 2015).

In the present study, the plasma levels of miR-103, miR-107, miR-194 and miR-210 were compared in 50 preoperative IGC patients and 50 healthy individuals. The result showed that the expression levels of miR-107, miR-194, and miR-210 were significantly lower in patients with IGC, whereas, the level of miR-103 exhibited no significant difference with control group. These findings are in contrast to those found by Rotkrua et al., who reported that the expression of all four miRNAs were higher in the mice model of DGC (Rotkrua et al., 2013). The main reason for this inconsistency might be largely due to the difference in the host species. Recently, the same group reported that, in contrast to the animal model, the plasma levels of miR-103, miR-107, and miR-194 are not significantly changed in human plasma and are not suitable for human DGC diagnosis (Oze et al., 2017). However, the results of the current study showed downregulations of miR-107, miR-194, and miR-210. The type of gastric cancer (diffuse-type versus intestinal-type) and the methods of relative quantification calculations could be other possible reasons for the disagreement. The earlier studies used "comparative CT (or ΔΔCT) method, while in the current study, the calculations were performed using Pfaffl method with the Relative Expression Software tool, which is more reliable (Pfaffl et al., 2002). On the other hand, the main limitation of the current study was difficulty in finding more plasma specimens from IGC patients who had not been received therapy and the sample size of more than 50 IGC specimen would have been more appropriate.

ROC curve analysis showed that IGC patients could be distinguished from healthy individuals at the cutoff levels of 0.504, 0.266, and 0.394 of miR-107 (sensitivity=93.8% and specificity=78.8%) , miR-194 (sensitivity=87.5% and specificity=75.8%), and miR-210 (sensitivity=100% and specificity=72.7%), respectively.

Furthermore, comparison of the plasma levels of these three miRNAs in different clinicopathological stages showed that the expression levels of the miRNAs were not significantly different among four stages. However, each stage showed lower plasma levels when compared with the control group. The results indicate that the differential expression of miR-107, miR-194, and miR-210 could not be used for staging intestinal-type gastric cancer. The finding is in accordance with some previous studies that evaluated expression levels of microRNAs in different stages of gastric cancer (Li et al., 2012). Nevertheless, some studies reported differential expression of some microRNAs in different stages of gastric cancer. Song et al. showed that the serum expression levels of miR-221, miR-744 and miR-376c were higher in poorly differentiated GC patients than in patients with well or moderately differentiated gastric cancer (Song et al., 2012). Mir-143 and miR-195 were also associated with clinicopathological parameters, including depth of invasion and lymph node metastasis (Guo et al., 2013).

On the other hand, some of these miRNAs were studied in other types of malignant disease, including colorectal cancer (Luo et al., 2011), breast cancer (Stuckrath et al., 2015; Xiong et al., 2017), lung cancer (Zhu et al., 2016; Qu et al., 2017), colorectal cancer (Nonaka et al., 2015; Basati et al., 2016; Wang et al., 2016b), glioma (Ji et al., 2015), hepatocellular carcinoma (Zhao et al., 2015; Zhang et al., 2017), and clear cell renal cell carcinoma (Li et al., 2017). However, combined expression profile of miR-107, miR-194 and miR-210 were only evaluated in gastric cancer.

In Conclusion, the results of this study indicate that miR-107, miR-194 and miR-210 were downregulated in the plasma samples of patients with intestinal-type of gastric cancer and suggest them as potential non-invasive biomarkers for detection of IGC.
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